SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ: SLS · USD

$10.4

-1.76 (-14.5%)· Recorded snapshot

Market cap	2.1B
Net income (ttm)	-32.5M
EPS (ttm)	-$0.21
Shares out	201.9M
Volume	23,031,366
Beta	2.57

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -32.5M
EPS (ttm): -$0.21
Market cap: 2.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-39.6

P25 n/aP50 n/aP75 n/a

ROIC-25

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SLS indicators

Market & fundamental data

Available fields

176

Groups with data

Currency

USD

Showing 176 of 176 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001390478
Company name	SELLAS Life Sciences Group, Inc.
Country	United States
Country code	US
CUSIP number	81642T209
Earnings date	2026-11-11
Earnings time	amc
Employees	13
Employees change	-2
Employees growth	-13.33%
Enterprise value	$2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US81642T2096
Last 10-K release date	2026-03-19
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2019-11-08
Last stock split type	Reverse
Market cap	$2.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$10.41
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SLS
U.S. state	New York
Website	https://sellaslifesciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-2.04%
FCF / EV yield	-1.47%
FCF yield	-1.37%
P/B ratio	17.85x
Price / tangible book value	15.26x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.5M
ROA	-23.3%
ROA (5Y)	-96.21%
ROCE	-24.03%
ROE	-39.63%
ROIC	-25.05%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	14
EPS growth years	3
Net income growth years	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-33.1M
EPS	$-0.21
FCF per share	$-0.14
Financing cash flow	$141.5M
Free cash flow	$-28.4M
Free cash flow minus SBC	$-31.2M
Net cash flow	$113M
Net income	$-32.5M
Operating cash flow minus SBC	$-31.2M
Operating income	$-33.1M
Stock-based compensation	$2.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.68
Debt / equity	0.01
Goodwill	$1.9M
Long-term assets	$2.9M
Long-term liabilities	$157,000
Net cash (debt)	$137.6M
Net cash / market cap	6.64%
Net cash growth	460.29%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$710,000
Shareholders' equity	$137.7M
Tangible book value	$135.7M
Tangible book value per share	$0.67
Total assets	$145.4M
Total cash	$138.3M
Total debt	$737,000
Total liabilities	$7.7M
WACC	18.38%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$142.5M
Current liabilities	$7.6M
Current ratio	18.83
Net working capital	$-2.8M
Quick ratio	18.28
Working capital	$134.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-86.04%
Dividend yield	0%
Shareholder yield	-86.04%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$9.84
1D price change	-14.5%
1M price change	-11.46%
1M total return	-11.46%
1W price change	-14.19%
1W total return	-14.19%
1Y price change	429.9%
1Y return CAGR	430.5%
1Y total return	429.9%
20-day SMA	$11.46
200-day SMA	$8.51
3M price change	-5.12%
3M total return	-5.12%
3Y price change	998.76%
3Y return CAGR	122.27%
3Y total return	998.76%
50-day SMA	$12.30
50-day SMA vs 200-day SMA	50over200
52-week high	$15.88
52-week high date	2026-06-30
52-week low	$1.39
52-week low date	2025-12-02
5Y price change	20.23%
5Y return CAGR	3.76%
5Y total return	20.23%
6M price change	110.66%
6M total return	110.66%
All-time high	$554.50
All-time high date	2018-04-03
All-time low	$0.50
All-time low date	2024-01-26
Average true range (ATR)	$1.02
Average volume	6.4M
Beta (1Y)	0.41
Beta (2Y)	0.7
Beta (5Y)	2.57
Change from 52-week high	-34.46%
Change from 52-week low	648.56%
Change from all-time high	-98.15%
Change from all-time low	1,961.77%
Change from open	-14.71%
Day's gap	0.25%
Dollar volume	$239.6M
High price	$12.35
Low price	$9.71
Monthly RSI	59.99
Open price	$12.20
Position in 52-week range	26.33%
Premarket change	-0.33%
Premarket close	$12.17
Premarket price	$12.13
Premarket volume	1.1M
Previous close	$12.17
Price vs 150-day SMA	4.45%
Price vs 20-day SMA	-10.26%
Price vs 200-day SMA	20.74%
Price vs 50-day SMA	-16.45%
Relative volume	3.57
RSI	41.76
Sharpe ratio	2.04
Sharpe ratio (3Y)	1.29
Sharpe ratio (5Y)	0.5
Sortino ratio	3.52
Sortino ratio (3Y)	2.09
Sortino ratio (5Y)	0.78
Volume	23M
Weekly RSI	50.76
YTD price change	172.68%
YTD total return	172.68%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	201.1M
Float percentage	99.61%
Shares change (QoQ)	9.68%
Shares change (YoY)	86.04%
Shares held by insiders	0.39%
Shares held by institutions	36.97%
Shares outstanding	201.9M
Short % of float	27.41%
Short % of shares	27.3%
Short ratio	8.6 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	525

Deeper analysis on SLS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SLS report

Is a complete SLS research report available?

No complete published report is available for SELLAS Life Sciences Group, Inc. (SLS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

SELLAS Life Sciences Group, Inc. (SLS)

Price

Financial snapshot

Fair-value bridge

Latest news · SLS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SLS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on SLS

Frequently asked questions